{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:08:11Z","timestamp":1774566491992,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.arbres.2017.01.014","type":"journal-article","created":{"date-parts":[[2017,4,22]],"date-time":"2017-04-22T01:31:48Z","timestamp":1492824708000},"page":"547-553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Post-bronchodilator Reversibility of FEV 1 and Eosinophilic Airway Inflammation in COPD"],"prefix":"10.1016","volume":"53","author":[{"given":"Kun-Ta","family":"Chou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang-Cheng","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Han","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiang-Fen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Kuo","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Min","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent Yi-Fong","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diahn-Warng","family":"Perng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2017.01.014_bib0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.6061\/clinics\/2012(11)19","article-title":"Airway disease: similarities and differences between asthma, COPD and bronchiectasis","volume":"67","author":"Athanazio","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.arbres.2017.01.014_bib0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.arbres.2012.04.001","article-title":"Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery","volume":"48","author":"Miravitlles","year":"2012","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2017.01.014_bib0015","series-title":"Diagnosis of disease of chronic airflow limitation: Asthma","author":"GINA-GOLD","year":"2016"},{"key":"10.1016\/j.arbres.2017.01.014_bib0020","series-title":"Global strategy for asthma management and prevention 2016","author":"Global Initiative for Asthma (GINA)","year":"2016"},{"key":"10.1016\/j.arbres.2017.01.014_bib0025","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1378\/chest.10-2974","article-title":"Bronchodilator reversibility in COPD","volume":"140","author":"Hanania","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2017.01.014_bib0030","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.arbres.2017.01.014_bib0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1378\/chest.126.2.375","article-title":"Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment","volume":"126","author":"Perng","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2017.01.014_bib0040","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00408-005-2586-8","article-title":"Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility","volume":"184","author":"Perng","year":"2006","journal-title":"Lung"},{"key":"10.1016\/j.arbres.2017.01.014_bib0045","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1183\/09031936.00115308","article-title":"Anti-inflammatory effects of salmeterol\/fluticasone, tiotropium\/fluticasone or tiotropium in COPD","volume":"33","author":"Perng","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2017.01.014_bib0050","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00408-014-9591-8","article-title":"Exhaled nitric oxide predicts eosinophilic airway inflammation in COPD","volume":"192","author":"Chou","year":"2014","journal-title":"Lung"},{"key":"10.1016\/j.arbres.2017.01.014_bib0055","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2001\u20132013. http:\/\/www.goldcopd.org\/guidelines-global-strategy-for-diagnosis-management.html."},{"key":"10.1016\/j.arbres.2017.01.014_bib0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1164\/ajrccm\/138.2.317","article-title":"Clinical interpretation of airway response to a bronchodilator. Epidemiologic considerations","volume":"138","author":"Dales","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.arbres.2017.01.014_bib0065","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1378\/chest.129.5.1344","article-title":"Clinical applications of induced sputum","volume":"129","author":"Brightling","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2017.01.014_bib0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000353863","article-title":"Diagnostic accuracy measures","volume":"36","author":"Eusebi","year":"2013","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.arbres.2017.01.014_bib0075","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1378\/chest.65.5.552","article-title":"Criteria for the assessment of reversibility in airways obstruction. Report of the Committee on Emphysema American College of Chest Physicians","volume":"65","author":"College RotCoEA","year":"1974","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2017.01.014_bib0080","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1183\/09031936.05.00035205","article-title":"Interpretative strategies for lung function tests","volume":"26","author":"Pellegrino","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2017.01.014_bib0085","series-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2010 Version","author":"Global Initiative for Chronic Obstructive Lung Disease (GOLD)","year":"2016"},{"key":"10.1016\/j.arbres.2017.01.014_bib0090","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.arbres.2011.10.007","article-title":"Clinical phenotypes of COPD: identification, definition and implications for guidelines","volume":"48","author":"Miravitlles","year":"2012","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2017.01.014_bib0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/MCP.0000000000000118","article-title":"The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges","volume":"21","author":"Barrecheguren","year":"2015","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.arbres.2017.01.014_bib0100","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2147\/COPD.S88667","article-title":"What pulmonologists think about the asthma-COPD overlap syndrome","volume":"10","author":"Miravitlles","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2017.01.014_bib0105","first-page":"1745","article-title":"Is a previous diagnosis of asthma a reliable criterion for asthma-COPD overlap syndrome in a patient with COPD?","volume":"10","author":"Barrecheguren","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2017.01.014_bib0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.chest.2015.08.017","article-title":"Asthma-COPD overlap","volume":"149","author":"Barnes","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2017.01.014_bib0115","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1164\/ajrccm.162.5.9910112","article-title":"Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease","volume":"162","author":"Papi","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2017.01.014_bib0120","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2147\/COPD.S80992","article-title":"Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease","volume":"10","author":"Zanini","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2017.01.014_bib0125","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0140-6736(00)02872-5","article-title":"Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial","volume":"356","author":"Brightling","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2017.01.014_bib0130","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/rccm.200508-1321OC","article-title":"Antiinflammatory effects of salmeterol\/fluticasone propionate in chronic obstructive lung disease","volume":"173","author":"Barnes","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2017.01.014_bib0135","first-page":"283","article-title":"Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma","volume":"7","author":"Kitaguchi","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2017.01.014_bib0140","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/thx.2008.108027","article-title":"The overlap syndrome of asthma and COPD: what are its features and how important is it?","volume":"64","author":"Gibson","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2017.01.014_bib0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1378\/chest.15-1055","article-title":"Defining the asthma-COPD overlap syndrome in a COPD cohort","volume":"149","author":"Cosio","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2017.01.014_bib0150","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12955-014-0120-5","article-title":"Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems","volume":"12","author":"Miravitlles","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.arbres.2017.01.014_bib0155","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.arbres.2013.12.013","article-title":"Distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke","volume":"50","author":"Golpe","year":"2014","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2017.01.014_bib0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.niox.2016.02.003","article-title":"Diagnostic performance of the measurement of nitric oxide in exhaled air in the diagnosis of COPD phenotypes","volume":"54","author":"Alcazar-Navarrete","year":"2016","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.arbres.2017.01.014_bib0165","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/thorax.58.8.659","article-title":"Bronchodilator reversibility testing in chronic obstructive pulmonary disease","volume":"58","author":"Calverley","year":"2003","journal-title":"Thorax"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030028961730039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030028961730039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T13:57:03Z","timestamp":1535896623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030028961730039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S030028961730039X"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2017.01.014","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-bronchodilator Reversibility of FEV1 and Eosinophilic Airway Inflammation in COPD","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2017.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}